Feasibility Study of Chemoradiation, TRAstuzumab and Pertuzumab in Resectable HER2+ Esophageal Carcinoma
Clinical trial NCT02120911 · COMPLETED
Trial details
- NCT number
- NCT02120911
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
- Status
- COMPLETED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2014-01-01
- Primary completion
- 2017-02-01
- Enrollment
- 40
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.